Edit |   |
---|---|
Product Name | Dabrafenib |
Description | Dabrafenib (GSK2118436) is a small molecule which can act as a B-Raf mutant inhibitor. It is provided as an off-white powder. This product acts on the following target types: Kinase. This product acts on the following biochemical pathways: Autophagy. This product may be of interest in the following research areas and diseases: Cellular stress, Cell death, Cancer. This product may act as a Coronavirus inhibitor: Inibits NEK9, which interacts with SARS-CoV-2 Nsp9. Please note that our chemical products are for scientific research use only and are not for medical or veterinary use. This product can only be dispatched to a scientific business or laboratory address. Purity > 98% (TLC). Conforms to structure by NMR. MW: 519.6 g/mol |
Size | 5 mg, 25 mg |
Concentration | n/a |
Applications | n/a |
Other Names | Dabrafenib, Dabrafenib (GSK2118436), N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide, GSK2118436, 1195765-45-7 |
Gene, Accession, CAS # | CAS: 1195765-45-7 |
Catalog # | abx282416 |
Price | please inquire |
Order / More Info | Dabrafenib from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950